| 261 | 0 | 103 |
| 下载次数 | 被引频次 | 阅读次数 |
多发性骨髓瘤是常见的恶性血液病，为有效提升多发性骨髓瘤的治疗效果，改善多发性骨髓瘤并发症，提高患者的生活质量，山东中医药学会肿瘤精准医学专业委员会，中华中医药学会血液病创新研究与转化平台，中国抗癌协会中西整合多发性骨髓瘤专业委员会组织专家，征集专家意见，制订共识。结合山东本省发病率等数据，在文献总结的基础上提出专家共识。共识内容涉及发病机制、中医病因病机及中西医治疗方案。尤其体现了化疗相关周围神经病变、化疗相关心脏毒性、嵌合抗原受体T(CAR-T)细胞治疗并发症方面的中医中药的独到特色，可以为临床提供指导。
Abstract：Multiple myeloma is a common malignant hematological disease. In order to effectively enhance the therapeutic effect of multiple myeloma,improve its complications,and improve patients' quality of life,the Professional Committee on Precision Oncology,Shandong Association of Traditional Chinese Medicine,Innovation and Translational Research Platform for Hematologic Diseases,China Association of Chinese Medicine,Professional Committee on Integrated Traditional Chinese and Western Medicine for Multiple Myeloma,Chinese Anti-Cancer Association organized experts to collect expert opinions and formulate this consensus. Based on data such as the incidence rate in Shandong Province and a summary of relevant literature,the expert consensus is put forward. Its contents cover the pathogenesis,disease cause and disease mechanism of traditional Chinese medicine(TCM),as well as treatment plans of TCM and Western medicine. In particular,it embodies the unique characteristics of TCM in chemotherapy-related peripheral neuropathy,chemotherapy-related cardiotoxicity,and complications of CAR-T cell therapy,and can guide clinical practice.
[1]蓝海，侯丽，郎海燕，等.常见血液病的中医分类与命名[J].中医杂志，2019,60(9):750-753,778.
[2]马吉祥，郭晓雷，付振涛.山东省恶性肿瘤报告2021[M].济南：山东科学技术出版社，2022:110.
[3]中国医师协会血液科医师分会，中华医学会血液学分会.中国多发性骨髓瘤诊治指南（2024年修订）[J].中华内科杂志，2024,63(12):1186-1195.
[4] VINCENT RAJKUMAR S, DIMOPOULOS M A,PALUMBO A,et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma[J]. Lancet Oncol,2014,15(12):e538-e548.
[5] KUMAR S K,CALLANDER N S,ADEKOLA K,et al.Multiple myeloma,version 2. 2024,NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw,2023,21(12):1281-1301.
[6] RAGO A,GRAMMATICO S,ZA T,et al. Prognostic factors associated with progression of smoldering multiple myeloma to symptomatic form[J]. Cancer,2012,118(22):5544-5549.
[7] KYLE R A,REMSTEIN E D,THERNEAU T M,et al.Clinical course and prognosis of smoldering(asymptomatic)multiple myeloma[J]. N Engl J Med,2007,356(25):2582-2590.
[8]陈信义，杨文华.中医血液病学[M].北京：中国中医药出版社，2019:138-145.
[9]黄振翘，梁冰，陈信义，等.实用中医血液病学[M].上海：上海科学技术出版社，2005:455-464.
[10] DURIE B G,SALMON S E. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features,response to treatment,and survival[J]. Cancer,1975,36(3):842-854.
[11] PALUMBO A,AVET-LOISEAU H,OLIVA S,et al. Revised international staging system for multiple myeloma:a report from international myeloma working group[J]. J Clin Oncol,2015,33(26):2863-2869.
[12] HAN WM,JIN YY,XU M,et al. Prognostic value of circulating clonal plasma cells in newly diagnosed multiple myeloma[J]. Hematology,2021,26(1):510-517.
[13] YAO W Q,YANG H F,YOU H Y,et al. The prognostic significance of circulating plasma cells in newly diagnosed multiple myeloma patients[J]. Front Oncol,2023,13:1266868.
[14] TERPOS E,MUSTO P,ENGELHARDT M,et al. Management of patients with multiple myeloma and COVID-19 in the post pandemic era:a consensus paper from the European Myeloma Network(EMN)[J].Leukemia,2023,37(6):1175-1185.
[15]多发性骨髓瘤骨病外科治疗专家共识（2022版）[J].中国肿瘤临床，2022,49(15):800.
[16] DRAYSON M T,BOWCOCK S,PLANCHE T,et al. Levofloxacin prophylaxis in patients with newly diagnosed myeloma(TEAMM):a multicentre,double-blind,placebo-controlled,randomised,phase 3 trial[J]. Lancet Oncol,2019,20(12):1760-1772.
[17] BADEN LR,SWAMINATHAN S,ANGARONE M,et al.Prevention and treatment of cancer-related infections,version 2.2016,NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw,2016,14(7):882-913.
[18]中国抗癌协会血液肿瘤专业委员会，中华医学会血液学分会.中国多发性骨髓瘤骨病诊治指南（2022年版）[J].中华血液学杂志，2022,43(12):979-985.
[19]中国临床肿瘤学会老年肿瘤防治专家委员会.成人恶性肿瘤患者合并新型冠状病毒感染的诊治建议[J].中华肿瘤杂志，2023,45(3):191-202.
[20] MILLER P,PATEL S R,SKINNER R,et al. Joint consensus statement on the vaccination of adult and paediatric haematopoietic stem cell transplant recipients:Prepared on behalf of the British society of blood and marrow transplantation and cellular therapy(BSBMTCT),the Children’s cancer and Leukaemia Group(CCLG),and British Infection Association(BIA)[J]. J Infect,2023,86(1):1-8.
[21] YU M Y,YU J,ZHANG Y Y,et al. A novel circRNAmiRNA-mRNA network revealed exosomal circ-ATP10A as a biomarker for multiple myeloma angiogenesis[J].Bioengineered,2022,13(1):667-683.
[22] ZHANG Y Y,PISANO M,LI N H,et al. Exosomal circRNA as a novel potential therapeutic target for multiple myeloma-related peripheral neuropathy[J]. Cell Signal,2021,78:109872.
[23] YU M Y,JI L,LI S M,et al. Exosomal circ-CACNG2promotes cardiomyocyte apoptosis in multiple myeloma via modulating miR-197-3p/caspase3 axis[J]. Exp Cell Res,2022,417(2):113229.
[24] ZHANG Y Y,PISANO M,LI N H,et al. Exosomal circRNA as a novel potential therapeutic target for multiple myeloma-related peripheral neuropathy[J]. Cell Signal,2021,78:109872.
[25] SUN R J,LIU J,YU M Y,et al. Paeoniflorin ameliorates BiPN by reducing IL6 levels and regulating PARKIN-mediated mitochondrial autophagy[J]. Drug Des Devel Ther,2022,16:2241-2259.
[26] DUE?AS-CUELLAR R A,SANTANA C J C,MAGALH?ES A C M,et al. Scorpion toxins and ion channels:potential applications in cancer therapy[J]. Toxins,2020,12(5):326.
[27] WANG C,DAI S,ZHAO X T,et al. Celastrol as an emerging anticancer agent:Current status,challenges and therapeutic strategies[J]. Biomed Pharmacother,2023,163:114882.
[28]王艺华，马艳萍.马钱子碱对多发性骨髓瘤中成骨细胞及破骨细胞代谢的影响[J].中国实验血液学杂志，2011,19(2):399-403.
[29] CHEN Q,LU Z,JIN Y,et al. Triptolide inhibits Jak2transcription and induces apoptosis in human myeloproliferative disorder cells bearing Jak2V617F through caspase-3-mediated cleavage of Mcl-1[J]. Cancer Lett,2010,291(2):246-255.
[30] LUO Y,ZHANG P,ZENG H Q,et al. Ginsenoside Rg3induces apoptosis in human multiple myeloma cells via the activation of Bcl-2-associated X protein[J].Mol Med Rep,2015,12(3):3557-3562.
[31] STAROBOVA H,MONTELEONE M,ADOLPHE C,et al. Vincristine-induced peripheral neuropathy is driven by canonical NLRP3 activation and IL-1β release[J].J Exp Med,2021,218(5):e20201452.
[32] YAMAMOTO S,EGASHIRA N. Pathological mechanisms of bortezomib-induced peripheral neuropathy[J]. Int J Mol Sci,2021,22(2):888.
[33] KOEPPEN S. Treatment of multiple myeloma:thalidomide-,bortezomib-,and lenalidomide-induced peripheral neuropathy[J]. Oncol Res Treat,2014,37(9):506-513.
[34] DIMITROVA A,MURCHISON C,OKEN B. Acupuncture for the treatment of peripheral neuropathy:a systematic review and meta-analysis[J]. J Altern Complement Med,2017,23(3):164-179.
[35]彭玉晓，胡小冬，杜慧姣，等.化疗致周围神经病变非药物干预的研究进展[J].中华护理杂志，2019,54(12):1907-1910.
[36]RAWAT P S,JAISWAL A,KHURANA A,et al.Doxorubicin-induced cardiotoxicity:an update on the molecular mechanism and novel therapeutic strategies for effective management[J]. Biomed Pharmacother,2021,139:111708.
[37] WU P ,OREN O ,GERTZ M A ,et al. Proteasome inhibitor-related cardiotoxicity:mechanisms,diagnosis,and management[J]. Curr Oncol Rep,2020,22(7):66.
[38] RENEAU J C,ASANTE D,VAN HOUTEN H,et al.Cardiotoxicity risk with bortezomib versus lenalidomide for treatment of multiple myeloma:a propensity matched study of 1,790 patients[J]. Am J Hematol,2017,92(2):E15-E17.
[39]张勇，武海明，马华.生脉注射液对乳腺癌表阿霉素多程化疗心脏毒性的作用研究[J].中西医结合心脑血管病杂志，2009,7(9):1030-1031.
[40]刘杰，罗莉，杨柱，等.参芪扶正注射液防治化疗诱导心脏毒性的Meta分析[J].中医肿瘤学杂志，2021,3(1):82-89.
[41] FU J Q,SUN R J,YU M Y,et al. Guicao Baidu decoction in mitigating chemotherapy-induced myocardial injury:case report and mechanism investigation[J].Nat Ther Adv,2024,7(3):15.
[42]王凡，巩平.炙甘草汤预防蒽环类药物心脏毒性的临床观察[J].现代肿瘤医学，2016,24(16):2610-2614.
[43]林素真.炙甘草汤改善乳腺癌蒽环类化疗致心肌毒性临床分析及机制探究分析[J].中外医疗，2019,38(25):173-175.
[44]郭芮，司廷林.当归四逆汤方证的临床应用[J].中国中医药现代远程教育，2019,17(3):59-61.
[45]徐资怡，石金凤，鲜静，等.雷公藤红素单用和联用抗肿瘤作用机制的研究进展[J].中草药，2021,52(14):4372-4385.
[46]陈玉瑙.全蝎解毒汤联合化疗治疗急性白血病的疗效观察[J].实用中西医结合临床，2020,20(1):47-48.
[47] COSTA B A ,COSTA T A ,SARAVIA S D ,et al.Thromboembolic risk of carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for newly diagnosed multiple myeloma:a comparative systematic review and meta-analysis[J]. Am J Hematol,2024,99(6):1056-1065.
[48]黄孝玲，张雅月，胡凯，等.基于“壮火”理论辨治嵌合抗原受体T细胞治疗相关细胞因子释放综合征的经验[J].北京中医药，2024,43(4):393-396.
[49] SUN X Q,PISANO M,XU L J,et al. Baicalin regulates autophagy to interfere with small intestinal acute graft-versus-host disease[J]. Sci Rep,2022,12(1):6551.
[50]于漫亚，孔凡盛，张杰，等.单倍体造血干细胞移植后肠道急性移植物抗宿主病的发病机制[J].中国组织工程研究，2022,26(30):4806-4811.
[51]崔兴，孙小琪，郑伟，等.黄芩汤调控自噬干预小鼠肠道急性移植物抗宿主病的机制[J].中国组织工程研究，2022,26(7):1057-1062.
[52] VINCENT RAJKUMAR S,DIMOPOULOS M A,PALUMBO A,et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma[J].Lancet Oncol,2014,15(12):538-548.
[53]孙涛. 2023版CSCO肿瘤心脏病学指南中化疗及免疫治疗心脏毒性的更新要点解读[J].实用肿瘤杂志，2023,38(5):434-439.
基本信息:
DOI：10.16295/j.cnki.0257-358x.2025.10.002
中图分类号:R733.3
引用信息:
[1]崔兴,杨烨,孙润洁.多发性骨髓瘤及并发症中西医结合诊疗规范[J].山东中医杂志,2025,44(10):1059-1071.DOI:10.16295/j.cnki.0257-358x.2025.10.002.
基金信息:
山东省地方标准项目（编号：202313）; 国家自然科学基金项目（编号：82274491,82074348）; 山东省自然科学基金创新发展联合基金项目（编号：ZR2023LZL009）